These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 25392020)

  • 1. Insulin requirement profiles in Japanese hospitalized subjects with type 2 diabetes treated with basal-bolus insulin therapy.
    Shimoda S; Okubo M; Koga K; Sekigami T; Kawashima J; Kukidome D; Igata M; Ishii N; Shimakawa A; Matsumura T; Motoshima H; Furukawa N; Nishida K; Araki E
    Endocr J; 2015; 62(2):209-16. PubMed ID: 25392020
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial.
    Aronson R; Reznik Y; Conget I; Castañeda JA; Runzis S; Lee SW; Cohen O;
    Diabetes Obes Metab; 2016 May; 18(5):500-7. PubMed ID: 26854123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypoglycemia observed during continuous glucose monitoring in patients with type 2 diabetes mellitus treated by subcutaneous insulin injection.
    Ito H; Abe M; Shinozaki M; Oshikiri K; Yamashita H; Nakashima M; Takaki A; Yukawa C; Furusho M; Antoku S; Mifune M; Togane M
    Diabetes Technol Ther; 2013 Jul; 15(7):586-90. PubMed ID: 23578166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin requirement profiles and related factors of insulin pump therapy in patients with type 2 diabetes.
    Yang X; Deng H; Zhang X; Yang D; Yan J; Yao B; Weng J; Xu W
    Sci China Life Sci; 2019 Nov; 62(11):1506-1513. PubMed ID: 31197759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
    Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
    Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
    Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
    Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A bridge to insulin pump therapy: twice-daily regimen with NPH and detemir insulins during initial treatment of youth with type 1 diabetes mellitus.
    Cengiz E; Sherr JL; Erkin-Cakmak A; Weinzimer SA; Burke EN; Sikes KA; Urban AD; Tamborlane WV
    Endocr Pract; 2011; 17(6):862-6. PubMed ID: 21550949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
    Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus.
    King AB; Clark D; Wolfe GS
    Endocr Pract; 2012; 18(3):382-6. PubMed ID: 22440988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of insulin supplementation for correction of bedtime hyperglycemia in hospitalized patients with type 2 diabetes.
    Vellanki P; Bean R; Oyedokun FA; Pasquel FJ; Smiley D; Farrokhi F; Newton C; Peng L; Umpierrez GE
    Diabetes Care; 2015 Apr; 38(4):568-74. PubMed ID: 25665812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
    Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
    Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin management of type 2 diabetes mellitus.
    Petznick A
    Am Fam Physician; 2011 Jul; 84(2):183-90. PubMed ID: 21766768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese people with type 2 diabetes using basal insulin and oral antihyperglycaemic drugs: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 2).
    Terauchi Y; Koyama M; Cheng X; Takahashi Y; Riddle MC; Bolli GB; Hirose T
    Diabetes Obes Metab; 2016 Apr; 18(4):366-74. PubMed ID: 26662838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective review of insulin requirements in patients using U-500 insulin hospitalized to a Veterans Affairs Hospital.
    Kedia R; Desouza C; Smith LM; Shivaswamy V
    J Diabetes Complications; 2017 May; 31(5):874-879. PubMed ID: 28274680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Descriptive Analysis of Long- and Intermediate-Acting Insulin and Key Safety Outcomes in Adults with Type 2 Diabetes Mellitus.
    Kent DJ; McMahill-Walraven CN; Panozzo CA; Pawloski PA; Haynes K; Marshall J; Brown J; Eichelberger B; Lockhart CM
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1162-1171. PubMed ID: 31405345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study.
    Mathieu C; Storms F; Tits J; Veneman TF; Colin IM
    Acta Clin Belg; 2013; 68(1):28-33. PubMed ID: 23627191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbohydrate-to-insulin ratio is estimated from 300-400 divided by total daily insulin dose in type 1 diabetes patients who use the insulin pump.
    Kuroda A; Yasuda T; Takahara M; Sakamoto F; Kasami R; Miyashita K; Yoshida S; Kondo E; Aihara K; Endo I; Matsuoka TA; Kaneto H; Matsumoto T; Shimomura I; Matsuhisa M
    Diabetes Technol Ther; 2012 Nov; 14(11):1077-80. PubMed ID: 23101953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effort required to achieve and maintain optimal glycemic control.
    Rosenthal ES; Bashan E; Herman WH; Hodish I
    J Diabetes Complications; 2011; 25(5):283-8. PubMed ID: 21367626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine.
    King AB; Clark D; Wolfe GS
    Endocr Pract; 2012; 18(4):558-62. PubMed ID: 22548951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.